Embrace(TM) Hydrogel Embolic System
Instylla, Inc. · Decision date Oct 21, 2026
What did the FDA approve?
The FDA recorded approval on 2026-10-21 of P250003/S010, a Special (Immediate Track) supplement to the Embrace Hydrogel Embolic System PMA held by Instylla, Inc. The supplement type is listed under the process-change reason covering manufacturer, sterilizer, packager or supplier, and the device category is Embolization Agent, Vascular.
The reported purpose is a change to product positioning within the pouch before moist heat sterilization of the precursor kit. This is a manufacturing notice about the precursor kit, not a new approval of the whole system and not an original PMA. The record does not specify the prior positioning, the new positioning, the pouch or kit components affected, or any sterilization validation outcomes; safety or clinical effectiveness is not established by this entry.
The identifier P250003/S010 links the supplement to parent PMA P250003.
FDA approval order statement
Approval for a change to the product positioning within the pouch prior to moist heat sterilization of the precursor kit of the Embrace Hydrogel Embolic System (HES).
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 21, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250003/S010
- Regulatory pathway
- PMA supplement
- Applicant
- Instylla, Inc.
- Product code
- QVG
- Decision code
- APPR
- Decision date
- Oct 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Embolization Agent, Vascular.
- Applicant
- Instylla, Inc.
- Product code
- QVG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250003 · Original PMA
Embrace(TM) Hydrogel Embolic System
P250003/S009 · Related supplement
Embrace Hydrogel Embolic System
P250003/S010 received
Application receipt date recorded by FDA.
P250003/S010 · FDA decision
Special (Immediate Track)
P250003/S008 · Related supplement
Embrace(TM) Hydrogel Embolic System
P250003/S011 · Related supplement
Embrace Hydrogel Embolic System
Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Instylla, Inc. | PMA approval | Aug 5, 2025 | FDA | |
Embrace Hydrogel Embolic SystemP250003/S009 | Instylla, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Embrace(TM) Hydrogel Embolic SystemP250003/S008 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Embrace Hydrogel Embolic SystemP250003/S011 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Instylla, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., North Bldg., Bedford, MA, 01730
Sources and methodology
- Original FDA record: P250003/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
